We are thrilled to be attending the AACR Immuno-Oncology Conference in Los Angeles, California from February 18th to 21st. Founded in 1907, the American Association for Cancer Research (AACR) is the oldest and largest cancer research organization in the world. This annual conference unites scientists, researchers, industry experts, and investors in advancing the understanding of cancer etiology, prevention, and treatment. Be sure to visit our booth #208 to learn how Biocytogen’s animal models and fully human antibody discovery services are driving oncology drug development.
What is the AACR Immuno-Oncology?
The AACR Immuno-Onocology Conference will cover the very best of basic, translational, and clinical research in immunology, inflammation, and immunotherapies for cancer, immuno-oncology drugs, inflammatory modulators, vaccines, and cellular therapies. Over the three days, experts across the field will be conducting lectures, symposiums, educational sessions, presentations, and exhibits, further promoting the exchange of knowledge, innovation, and collaboration.
Event Overview
Date: February 18th-21st, 2026
Venue: JW Marriott Los Angeles L.A. LIVE, 900 W Olympic Blvd, Los Angeles, CA
Event Schedule
For more information, please refer to the event program.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Los Angeles!
